A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer (NCT07054190)
A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
Who can join: Review the eligibility criteria below.
Location: Los Angeles Cancer Network — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- Los Angeles Cancer Network — Los Angeles, California
- Community Clinical Trials — Orange, California
- West Cancer Center — Germantown, Tennessee
- West Virginia University — Morgantown, West Virginia
- Hospital Aleman de Buenos Aires — Buenos Aires,
- Centro Médico Fleischer — Buenos Aires,
- Centro Oncologico Korben — Ciudad Autonoma Buenos Aires,
- Hospital Araujo Jorge — Goiânia, Goiás
- Hospital do Cancer de Pernambuco - HCP — Recife, Pernambuco
- Irmandade Da Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul
- Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda — São Paulo, São Paulo
- Sunnybrook Odette Cancer Centre — Toronto, Ontario
- Centre Hospitalier de l'Universite de Montreal (CHUM) — Montreal, Quebec
- Jewish General Hospital — Montreal, Quebec
- McGill University Health Center — Montreal, Quebec
- Das Brustzentrum — Berlin,
- HELIOS Klinikum Berlin-Buch — Berlin,
- Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden — Dresden,
- Kliniken Essen-Mitte — Essen,
- Universitätsklinikum Heidelberg — Heidelberg,
- St. Vincenz-Krankenhaus GmbH Paderborn Frauen- und Kinderklinik St. Louise — Paderborn,
- HELIOS Klinikum Schwerin — Schwerin,
- Seoul National University Hospital — Seoul,
- Severance Hospital, Yonsei University Health System — Seoul,
- Asan Medical Center. — Seoul,
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.